Department of Medicine, Weill Cornell Medicine, New York, NY 10021, USA; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA; NewYork-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY 10065, USA.
Department of Medicine, Weill Cornell Medicine, New York, NY 10021, USA; NewYork-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY 10065, USA.
Cancer Cell. 2020 Nov 9;38(5):661-671.e2. doi: 10.1016/j.ccell.2020.09.007. Epub 2020 Sep 15.
Patients with cancer may be at increased risk of severe coronavirus disease 2019 (COVID-19), but the role of viral load on this risk is unknown. We measured SARS-CoV-2 viral load using cycle threshold (C) values from reverse-transcription polymerase chain reaction assays applied to nasopharyngeal swab specimens in 100 patients with cancer and 2,914 without cancer who were admitted to three New York City hospitals. Overall, the in-hospital mortality rate was 38.8% among patients with a high viral load, 24.1% among patients with a medium viral load, and 15.3% among patients with a low viral load (p < 0.001). Similar findings were observed in patients with cancer (high, 45.2% mortality; medium, 28.0%; low, 12.1%; p = 0.008). Patients with hematologic malignancies had higher median viral loads (C = 25.0) than patients without cancer (C = 29.2; p = 0.0039). SARS-CoV-2 viral load results may offer vital prognostic information for patients with and without cancer who are hospitalized with COVID-19.
癌症患者罹患 2019 年冠状病毒病（COVID-19）重症的风险可能增加，但病毒载量在此风险中的作用尚不清楚。我们对来自三家纽约市医院的 100 名癌症患者和 2914 名非癌症患者的鼻咽拭子标本进行逆转录聚合酶链反应（RT-PCR）检测，以测量 SARS-CoV-2 病毒载量。总体而言，高病毒载量患者的住院死亡率为 38.8%，中病毒载量患者为 24.1%，低病毒载量患者为 15.3%（p<0.001）。在癌症患者中也观察到类似的发现（高病毒载量组死亡率为 45.2%；中病毒载量组为 28.0%；低病毒载量组为 12.1%；p=0.008）。与非癌症患者相比，患有血液系统恶性肿瘤的患者病毒载量中位数更高（C 值为 25.0）（p=0.0039）。SARS-CoV-2 病毒载量结果可为因 COVID-19 住院的癌症患者和非癌症患者提供重要的预后信息。
